<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="other"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>etd</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Ege Tıp Dergisi</journal-title>
            </journal-title-group>
                            <issn pub-type="ppub">1016-9113</issn>
                                        <issn pub-type="epub">2147-6500</issn>
                                                                                            <publisher>
                    <publisher-name>Ege Üniversitesi</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.19161/etd.648470</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Health Care Administration</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Sağlık Kurumları Yönetimi</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <trans-title-group xml:lang="en">
                                    <trans-title>Autoimmune diseases during anti-TNF therapy: Coexisting disease? Drug-induced?</trans-title>
                                </trans-title-group>
                                                                                                                                                                                                <article-title>Anti-TNF tedavi seyrinde gelişen otoimmün hastalıklar: Eşlik eden hastalık mı? İlaca mı bağlı?</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-7919-6696</contrib-id>
                                                                <name>
                                    <surname>Çelik</surname>
                                    <given-names>Selda</given-names>
                                </name>
                                                                    <aff>Sağlık Bilimleri Üniversitesi, Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Romatoloji Kliniği</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20191025">
                    <day>10</day>
                    <month>25</month>
                    <year>2019</year>
                </pub-date>
                                                                <fpage>8</fpage>
                                        <lpage>10</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20181019">
                        <day>10</day>
                        <month>19</month>
                        <year>2018</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20190815">
                        <day>08</day>
                        <month>15</month>
                        <year>2019</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 1962, Ege Tıp Dergisi</copyright-statement>
                    <copyright-year>1962</copyright-year>
                    <copyright-holder>Ege Tıp Dergisi</copyright-holder>
                </permissions>
            
                                                                                                <trans-abstract xml:lang="en">
                            <p>Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and autoimmune diseases. With this use and longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to anti-TNF agents. Since these drugs are often prescribed to severe rheumatologic patients, there is a controversy about whether the autoimmune diseases that could be related to underlying disease or anti-TNF therapy. We aimed to discuss this subject under the light of literature.</p></trans-abstract>
                                                                                                                                    <abstract><p>Anti-TNF tedavilerin romatolojik ve otoimmün hastalıkların tedavisinde yaygın kullanımı ve uzun dönem takipleri ile birlikte, paradoksal olarak anti-TNF ilişkili otoimmün hastalıklarla ilgili artan sayıda bildiriler olmaktadır. Bu ilaçlar genelde ağır hastalık aktivitesi olan romatolojik hastalarda kullanıldığından, bazı durumlarda bu gelişen hastalıkların altta yatan hastalığa da bağlı olabilmesi ile ilgili çelişkiler bulunmaktadır. Giderek artan vaka serilerinden elde edilen bilgiler ışığında bu konuyu tartışmayı amaçladık</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>Anti-TNF tedavi</kwd>
                                                    <kwd>  otoimmün hastalık</kwd>
                                                    <kwd>  vaskülit</kwd>
                                                    <kwd>  sistemik lupus eritematoz</kwd>
                                            </kwd-group>
                            
                                                <kwd-group xml:lang="en">
                                                    <kwd>Anti-TNF therapy</kwd>
                                                    <kwd>  autoimmune diseases</kwd>
                                                    <kwd>  vasculitis</kwd>
                                                    <kwd>  systemic lupus erythematosus</kwd>
                                            </kwd-group>
                                                                                                                                        </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86(4):242-51.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:143-7.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">Font J, Cervera R, Ramos-Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004;33:217-30.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents A double-edged sword? Autoimmun Rev 2010;9(3):188-93.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol 2008;26 (Suppl. 49):S23-9.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc 2012;87(8):739-45.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">Jani M, Dixon WG, Kersley-Fleet L et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open 2017;3:e000314. doi:10.1136/rmdopen-2016000314.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
